Find clinical trials for Lymphoma in New York, NY
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Lymphoma trials near New York, NY, USA:
glofitamab and obinutuzumab is in treating patients with Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) who have not rec...
Phase 2
New York, New York, United States and 2 other locations
In this research study is looking to see how safe and effective belantamab mafodotin is in relapsed or refractory plasmablastic lymphoma or ...
Phase 2
New York, New York, United States and 2 other locations
a standard 3+3 design. Once the maximum tolerated dose (MTD) is determined amongst patients with relapsed or refractory grade 1-3a follicular lymphoma...
Phase 1, Phase 2
Hackensack, New Jersey, United States and 2 other locations
combination with mosunetuzumab injections for people with follicular lymphoma who haven't received treatment before. The investigators hypot...
Phase 2
New York, New York, United States
of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing)....
Phase 1
New York, New York, United States and 6 other locations
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...
Phase 1, Phase 2
Hackensack, New Jersey, United States and 89 other locations
patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a possible treatment option.ARV-3...
Phase 1
New York, New York, United States and 13 other locations
DS-3201b is an experimental drug that is being investigated in clinical research.Adults with non-Hodgkin lymphoma (NHL) may be able to join ...
Phase 1
New York, New York, United States and 20 other locations
This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have e...
Phase 1
New Hyde Park, New York, United States and 31 other locations
and ibrutinib in patients with previously treated mantle cell lymphoma to evaluate the efficacy of this combination, with the primary object...
Phase 2
New York, New York, United States and 8 other locations
Clinical trials
Research sites
Resources
Legal